Dr. Chari’s research interests include the development of novel chemotherapy regimens, including Phase 1 and 2 studies. He is principal investigator (PI) of several investigator-initiated trials and serves as the national and international PI of several industry-sponsored studies. As the Director of Clinical Research in the Multiple Myeloma Program at Mt Sinai New York, he oversaw the growth of a program renowned nationally for both high volume patient accruals and rigorous quality assurance. The program played a pivotal role in the approval of each of the most recent therapies to be approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma.

Dr. Chari received undergraduate degree from Stanford University and his medical degree from the David Geffen School of Medicine at University of California – Los Angeles. He completed his residency in internal medicine at Columbia University Medical Center and a fellowship in hematology and oncology at the University of California – San Francisco.  As of this fall, Dr Chari will be returning to UCSF as the Director or Multiple Myeloma at the University of California San Francisco.